Leukapheresis Market Size, Share & Trends Analysis Report By Product Type (Leukapheresis Devices, Leukapheresis Disposables), By Application (Research Application, Therapeutic Application), By End-use, By Region, And Segment Forecasts, 2025 - 2030

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $5,950	120 Pages	Grand View Research	January, 2025	GV19584340

Best Price Guarantee
Price	from $5,950
Length	120 Pages
Publisher	Grand View Research
Published Date	January, 2025
SKU	GV19584340

Table of Contents
Description

Leukapheresis Market Size & Trends

The global leukapheresis market size was estimated at USD 211.3 million in 2024 and is projected to grow at a CAGR of 11.05% from 2025 to 2030. The increasing prevalence of blood disorders and autoimmune diseases, technological advancements in leukapheresis procedures, and growing demand for personalized medicine are expected to drive the market growth. Moreover, the increasing investments in research and development activities are further contributing to the market growth.

The rising incidence of blood disorders like leukemia, lymphoma, and autoimmune diseases such as rheumatoid arthritis and multiple sclerosis are significantly driving the market growth. For instance, the Leukemia & Lymphoma Society reports that an estimated total of 184,720 people in the U.S. are expected to receive a diagnosis of leukemia, lymphoma, or myeloma in 2023. Similarly, in May 2023, a study in The Lancet involving 22 million people found autoimmune disorders affect 1 in 10 individuals, highlighting the influence of socioeconomic, seasonal, and regional factors and offers insights into the causes of these diseases, including Rheumatoid arthritis, Type 1 diabetes, and Multiple sclerosis. Thus, propelling the demand for leukapheresis over the forecast period.

The advancements in leukapheresis technologies are improving the efficiency, safety, and outcomes of the procedure. The introduction of automated systems, continuous flow centrifugation systems, and closed-system devices is expected to enhance the precision and effectiveness of leukapheresis. Thereby reducing the procedure times, minimizing donor discomfort, and optimizing cell collection yields. In October 2022, the Clinical Applications Committee of The American Society for Apheresis (ASFA), along with the IEC Therapy Subcommittee, AABB, and various other organizations, prepared a white paper. This document outlines guidelines for performing leukapheresis to retrieve mononuclear cells from pediatric and adult patients who are part of immune effector cell therapies, whether for commercial endeavors or research initiatives. Thus, anticipated to propel the market growth over the forecast period.

The shift towards personalized medicine approaches that tailor treatment strategies to individual patient profiles is fueling the demand for leukapheresis procedures. Leukapheresis plays a crucial role in cell-based therapies, such as chimeric antigen receptor (CAR) T-cell therapy and stem cell transplantation. In December 2023, an article in Transfusion and Apheresis Science underscored the challenges in manufacturing CAR-T cells, beginning with the extraction of T cells through leukapheresis from peripheral blood. The article emphasized the critical role of an effective leukapheresis product in achieving successful CAR-T cell therapy and highlighted the significance of comprehending the factors that impact T cell quality.

Global Leukapheresis Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global leukapheresis market report based on product type, application, end-use, and region:

Product Type Outlook (Revenue, USD Million, 2018 - 2030)
Leukapheresis Devices

Centrifugal Devices

Membrane Separators

Leukapheresis Disposables
Application Outlook (Revenue, USD Million, 2018 - 2030)
Research Application

Cancer Research

Immunology Research

Others

Therapeutics Application

Hematologic Disorders

Autoimmune Diseases

Others

End-use Outlook (Revenue, USD Million, 2018 - 2030)
Blood Centers
Academic & Research Institutes
Pharmaceutical & Biotechnology Companies
Hospitals & Clinics
Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America

U.S.

Canada

Mexico

Europe

Germany

UK

France

Italy

Spain

Denmark

Sweden

Norway

Asia Pacific

China

Japan

India

South Korea

Australia

Thailand

Latin America

Brazil

Argentina

South Africa

Saudi Arabia

UAE

Kuwait

Please note The report will be delivered in 2-3 business days upon order notification.

Chapter 1. Methodology and Scope: 1.1. Market Segmentation and Scope; 1.2. Market Definitions; 1.2.1. Product Type; 1.2.2. Application; 1.2.3. End Use; 1.3. Information analysis; 1.4. Market formulation & data visualization; 1.5. Data validation & publishing; 1.6. Information Procurement; 1.6.1. Primary Research; 1.7. Information or Data Analysis; 1.8. Market Formulation & Validation; 1.9. Market Model; 1.10. Objectives
Chapter 2. Executive Summary: 2.1. Market Outlook; 2.2. Segment Snapshot; 2.3. Competitive Landscape Snapshot
Chapter 3. Leukapheresis Market Variables, Trends & Scope: 3.1. Market Lineage Outlook; 3.1.1. Parent market outlook; 3.1.2. Related/ancillary market outlook.; 3.2. Market Dynamics; 3.2.1. Market driver analysis; 3.2.1.1. The increasing prevalence of blood disorders and autoimmune diseases; 3.2.1.2. Technological advancements in leukapheresis procedures; 3.2.1.3. Growing demand for personalized medicine; 3.2.1.4. Rising investments in research; 3.2.2. Market restraint analysis; 3.2.2.1. High equipment costs; 3.3. Leukapheresis Market Analysis Tools; 3.3.1. Industry Analysis - Porter’s; 3.3.2. PESTEL Analysis; 3.3.3. COVID-19 Impact Analysis
Chapter 4. Leukapheresis Market: Product Type Estimates & Trend Analysis: 4.1. Segment Dashboard; 4.2. Global Leukapheresis Market Product Type Movement Analysis; 4.3. Global Leukapheresis Market Size & Trend Analysis, by Product Type, 2018 to 2030 (USD Million); 4.4. Leukapheresis Devices; 4.4.1. Leukapheresis devices market estimates and forecasts, 2018 to 2030 (USD Million); 4.4.2. Centrifugal Devices; 4.4.2.1. Centrifugal Devices market estimates and forecasts, 2018 to 2030 (USD Million); 4.4.3. Membrane Separators; 4.4.3.1. Membrane separators market estimates and forecasts, 2018 to 2030 (USD Million); 4.5. Leukapheresis Disposables; 4.5.1. Leukapheresis disposables market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Leukapheresis Market: Application Estimates & Trend Analysis: 5.1. Segment Dashboard; 5.2. Global Leukapheresis Market Application Movement Analysis; 5.3. Global Leukapheresis Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million); 5.4. Research Application; 5.4.1. Research application market estimates and forecasts, 2018 to 2030 (USD Million); 5.4.2. Cancer Research; 5.4.2.1. Cancer research market estimates and forecasts, 2018 to 2030 (USD Million); 5.4.3. Immunology Research; 5.4.3.1. Immunology research market estimates and forecasts, 2018 to 2030 (USD Million); 5.4.4. Others; 5.4.4.1. Others market estimates and forecasts, 2018 to 2030 (USD Million); 5.5. Therapeutics Application; 5.5.1. Therapeutics application market estimates and forecasts, 2018 to 2030 (USD Million); 5.5.2. Hematologic Disorders; 5.5.2.1. Hematologic disorders market estimates and forecasts, 2018 to 2030 (USD Million); 5.5.3. I Autoimmune Diseases; 5.5.3.1. Autoimmune diseases market estimates and forecasts, 2018 to 2030 (USD Million); 5.5.4. Others; 5.5.4.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Leukapheresis Market: End Use Estimates & Trend Analysis: 6.1. Segment Dashboard; 6.2. Global Leukapheresis Market End Use Movement Analysis; 6.3. Global Leukapheresis Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million); 6.4. Blood Centers; 6.4.1. Blood centers institutes market estimates and forecasts, 2018 to 2030 (USD Million); 6.5. Academic & Research Institutes; 6.5.1. Academic & research institutes market estimates and forecasts, 2018 to 2030 (USD Million); 6.6. Pharmaceutical & Biotechnology Companies; 6.6.1. Pharmaceutical & biotechnology companies market estimates and forecasts, 2018 to 2030 (USD Million); 6.7. Hospitals & Clinics; 6.7.1. Hospitals & clinics market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 7. Leukapheresis Market: Regional Estimates & Trend Analysis by Product Type, Application, and End Use: 7.1. Regional Market Share Analysis, 2024 & 2030; 7.2. Regional Market Dashboard; 7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:; 7.4. North America; 7.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million); 7.4.2. U.S.; 7.4.2.1. Key country dynamics; 7.4.2.2. Regulatory framework; 7.4.2.3. Competitive scenario; 7.4.2.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million); 7.4.3. Canada; 7.4.3.1. Key country dynamics; 7.4.3.2. Regulatory framework; 7.4.3.3. Competitive scenario; 7.4.3.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million); 7.4.4. Mexico; 7.4.4.1. Key country dynamics; 7.4.4.2. Regulatory framework; 7.4.4.3. Competitive scenario; 7.4.4.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million); 7.5. Europe; 7.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million); 7.5.2. UK; 7.5.2.1. Key country dynamics; 7.5.2.2. Regulatory framework; 7.5.2.3. Competitive scenario; 7.5.2.4. UK market estimates and forecasts, 2018 to 2030 (USD Million); 7.5.3. Germany; 7.5.3.1. Key country dynamics; 7.5.3.2. Regulatory framework; 7.5.3.3. Competitive scenario; 7.5.3.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million); 7.5.4. France; 7.5.4.1. Key country dynamics; 7.5.4.2. Regulatory framework; 7.5.4.3. Competitive scenario; 7.5.4.4. France market estimates and forecasts, 2018 to 2030 (USD Million); 7.5.5. Italy; 7.5.5.1. Key country dynamics; 7.5.5.2. Regulatory framework; 7.5.5.3. Competitive scenario; 7.5.5.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million); 7.5.6. Spain; 7.5.6.1. Key country dynamics; 7.5.6.2. Regulatory framework; 7.5.6.3. Competitive scenario; 7.5.6.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million); 7.5.7. Norway; 7.5.7.1. Key country dynamics; 7.5.7.2. Regulatory framework; 7.5.7.3. Competitive scenario; 7.5.7.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million); 7.5.8. Sweden; 7.5.8.1. Key country dynamics; 7.5.8.2. Regulatory framework; 7.5.8.3. Competitive scenario; 7.5.8.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million); 7.5.9. Denmark; 7.5.9.1. Key country dynamics; 7.5.9.2. Regulatory framework; 7.5.9.3. Competitive scenario; 7.5.9.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million); 7.6. Asia Pacific; 7.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million); 7.6.2. Japan; 7.6.2.1. Key country dynamics; 7.6.2.2. Regulatory framework; 7.6.2.3. Competitive scenario; 7.6.2.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million); 7.6.3. China; 7.6.3.1. Key country dynamics; 7.6.3.2. Regulatory framework; 7.6.3.3. Competitive scenario; 7.6.3.4. China market estimates and forecasts, 2018 to 2030 (USD Million); 7.6.4. India; 7.6.4.1. Key country dynamics; 7.6.4.2. Regulatory framework; 7.6.4.3. Competitive scenario; 7.6.4.4. India market estimates and forecasts, 2018 to 2030 (USD Million); 7.6.5. Australia; 7.6.5.1. Key country dynamics; 7.6.5.2. Regulatory framework; 7.6.5.3. Competitive scenario; 7.6.5.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million); 7.6.6. South Korea; 7.6.6.1. Key country dynamics; 7.6.6.2. Regulatory framework; 7.6.6.3. Competitive scenario; 7.6.6.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million); 7.6.7. Thailand; 7.6.7.1. Key country dynamics; 7.6.7.2. Regulatory framework; 7.6.7.3. Competitive scenario; 7.6.7.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million); 7.7. Latin America; 7.7.1. Market estimates and forecasts, 2018 to 2030 (USD Million); 7.7.2. Brazil; 7.7.2.1. Key country dynamics; 7.7.2.2. Regulatory framework; 7.7.2.3. Competitive scenario; 7.7.2.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million); 7.7.3. Argentina; 7.7.3.1. Key country dynamics; 7.7.3.2. Regulatory framework; 7.7.3.3. Competitive scenario; 7.7.3.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million); 7.8. MEA; 7.8.1. Market estimates and forecasts, 2018 to 2030 (USD Million); 7.8.2. South Africa; 7.8.2.1. Key country dynamics; 7.8.2.2. Regulatory framework; 7.8.2.3. Competitive scenario; 7.8.2.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million); 7.8.3. Saudi Arabia; 7.8.3.1. Key country dynamics; 7.8.3.2. Regulatory framework; 7.8.3.3. Competitive scenario; 7.8.3.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million); 7.8.4. UAE; 7.8.4.1. Key country dynamics; 7.8.4.2. Regulatory framework; 7.8.4.3. Competitive scenario; 7.8.4.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million); 7.8.5. Kuwait; 7.8.5.1. Key country dynamics; 7.8.5.2. Regulatory framework; 7.8.5.3. Competitive scenario; 7.8.5.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 8. Competitive Landscape: 8.1. Company/Competition Categorization; 8.2. Strategy Mapping; 8.3. Company Market Position Analysis, 2024; 8.4. Company Profiles/Listing; 8.4.1. Charles River Laboratories International, Inc.; 8.4.1.1. Company overview; 8.4.1.2. Financial performance; 8.4.1.3. Product benchmarking; 8.4.1.4. Strategic initiatives; 8.4.2. Adacyte Therapeutics; 8.4.2.1. Company overview; 8.4.2.2. Financial performance; 8.4.2.3. Product benchmarking; 8.4.2.4. Strategic initiatives; 8.4.3. AllCells, LLC; 8.4.3.1. Company overview; 8.4.3.2. Financial performance; 8.4.3.3. Product benchmarking; 8.4.3.4. Strategic initiatives; 8.4.4. Asahi Kasei Medical; 8.4.4.1. Company overview; 8.4.4.2. Financial performance; 8.4.4.3. Product benchmarking; 8.4.4.4. Strategic initiatives; 8.4.5. Haemonetics Corporation; 8.4.5.1. Company overview; 8.4.5.2. Financial performance; 8.4.5.3. Product benchmarking; 8.4.5.4. Strategic initiatives; 8.4.6. Macopharma; 8.4.6.1. Company overview; 8.4.6.2. Financial performance; 8.4.6.3. Product benchmarking; 8.4.6.4. Strategic initiatives; 8.4.7. Cerus Corporation; 8.4.7.1. Company overview; 8.4.7.2. Financial performance; 8.4.7.3. Product benchmarking; 8.4.7.4. Strategic initiatives; 8.4.8. SB-Kawasumi Laboratories, Inc.; 8.4.8.1. Company overview; 8.4.8.2. Financial performance; 8.4.8.3. Product benchmarking; 8.4.8.4. Strategic initiatives; 8.4.9. StemExpress, LLC.; 8.4.9.1. Company overview; 8.4.9.2. Financial performance; 8.4.9.3. Product benchmarking; 8.4.9.4. Strategic initiatives; 8.4.10. Caltag Medsystems Limited; 8.4.10.1. Company overview; 8.4.10.2. Financial performance; 8.4.10.3. Product benchmarking; 8.4.10.4. Strategic initiatives; 8.4.11. Lonza Group AG; 8.4.11.1. Company overview; 8.4.11.2. Financial performance; 8.4.11.3. Product benchmarking; 8.4.11.4. Strategic initiatives; 8.4.12. ZenBio; 8.4.12.1. Company overview; 8.4.12.2. Financial performance; 8.4.12.3. Product benchmarking; 8.4.12.4. Strategic initiatives; 8.4.13. Terumo BCT, Inc.; 8.4.13.1. Company overview; 8.4.13.2. Financial performance; 8.4.13.3. Product benchmarking; 8.4.13.4. Strategic initiatives; 8.4.14. Macopharma SA; 8.4.14.1. Company overview; 8.4.14.2. Financial performance; 8.4.14.3. Product benchmarking; 8.4.14.4. Strategic initiatives; 8.4.15. Miltenyi Biotec; 8.4.15.1. Company overview; 8.4.15.2. Financial performance; 8.4.15.3. Product benchmarking; 8.4.15.4. Strategic initiatives; 8.4.16. Fresenius SE & Co. KGaA; 8.4.16.1. Company overview; 8.4.16.2. Financial performance; 8.4.16.3. Product benchmarking; 8.4.16.4. Strategic initiatives; 8.4.17. Guangzhou Daji Medical Science; 8.4.17.1. Company overview; 8.4.17.2. Financial performance; 8.4.17.3. Product benchmarking; 8.4.17.4. Strategic initiatives; 8.4.18. MEDICA S.p.A; 8.4.18.1. Company overview; 8.4.18.2. Financial performance; 8.4.18.3. Product benchmarking; 8.4.18.4. Strategic initiatives; 8.4.19. SB-Kawasumi Laboratories, Inc.; 8.4.19.1. Company overview; 8.4.19.2. Financial performance; 8.4.19.3. Product benchmarking; 8.4.19.4. Strategic initiatives; 8.4.20. PuriBlood Medical Co. Ltd.; 8.4.20.1. Company overview; 8.4.20.2. Financial performance; 8.4.20.3. Product benchmarking; 8.4.20.4. Strategic initiatives; 8.4.21. Beijing ZKSK Technology Co. Ltd.; 8.4.21.1. Company overview; 8.4.21.2. Financial performance; 8.4.21.3. Product benchmarking; 8.4.21.4. Strategic initiatives